Leveraging the Molecular Signatures of Cancer for Dynamic Network Modeling

2022-10
Tunçbağ , Nurcan
Ayar , Enes Sefa
Molecular heterogeneity and resistance to the treatment are among the obstacles in developing treatment strategies in cancer. Therefore, transforming patient-specific molecular data into clinically interpretable knowledge is fundamental in personalized medicine. However, not all molecular alterations drive cancer. The distinction of drivers from latent drivers and passengers, their cooperativity and exclusivity, and the temporal order of accumulation of molecular alterations is a crucial yet daunting, unsolved task. Early alterations in temporal order can inform about network rewiring and direct the identification of drug targets. The challenge in temporal modelling of cancer and the respective elucidation of the chronological order of molecular alterations, especially in terms of the evolution of networks beyond the alterations, remains elusive. The focus of this study is directly devoted to address this challenge. We developed an integrative computational modeling approach to reveal the network-based history of tumor progression and to design personalized therapeutic strategies based on the validated models. The core method in this approach is the graph-based cellular automata (GCA), which is a discrete dynamic model. GCA model can simulate complex systems by considering local interaction rules, and it gives insights into the underlying mechanism of complex behavior. The reference graph is a tissue-specific interactome consisting of protein-protein interactions and regulatory interactions. Proteins are assumed to have a state of being for cancer-driving or neutral/against cancer progression. We applied this model to the cell line-dependent data in DepMap which consists of both molecular alterations (mutation transcriptomic and proteomic data) and drug response. As a result of a rigorous dynamic network comparison we constructed a network-based taxonomy of the tumors both within each cancer type and cross-cancer-types. We expect that this approach from molecular alterations to dynamic networks will transform the already available large datasets to gain new clinically relevant insights and improve personalized medicine.

Suggestions

Dual function of programmed cell death 10 (PDCD10) in drug resistance
Urfali-Mamatoglu, Cagri; Kazan, Hasan Huseyin; Gündüz, Ufuk (2018-05-01)
Drug resistance, a major challenge in cancer chemotherapy, is a result of several mechanistic alterations including resistance to apoptosis. Apoptosis is a well-controlled cell death mechanism which is regulated by several signaling pathways. Alterations in structure, function, and expression pattern of the proteins involved in the regulation of apoptosis have been linked to drug resistance. Programmed Cell Death 10 (PDCD10) protein is recently associated with the regulation of cell survival and apoptosis. ...
Investigation of docetaxel and doxorubicin resistance in mcf-7 breast carcinoma cell line
Darcansoy İşeri, Özlem; Gündüz, Ufuk; Department of Biotechnology (2009)
Multidrug resistance phenotype of tumor cells describes resistance to wide range of structurally unrelated anticancer agents and is a serious limitation to effective chemotherapy. It is a multifactor yet not fully elucidated phenomenon by the involvement of diverse cellular pathways. Aim of this study was to investigate the resistance mechanisms developed against docetaxel and doxorubicin that are widely used in the treatment of breast cancer in model cell line MCF-7. Resistant sublines were developed by ap...
Molecular mechanisms of vincristine and paclitaxel resistance in mcf-7 cell line
Demirel Kars, Meltem; Gündüz, Ufuk; Department of Biotechnology (2008)
Resistance to broad spectrum of chemotherapeutic agents in cancer cell lines and tumors has been called multiple drug resistance (MDR). In this study, the molecular mechanisms of resistance to two anticancer agents (paclitaxel and vincristine) in mammary carcinoma cell line MCF-7 were investigated. MCF-7 cells were selected in the presence of paclitaxel and vincristine by stepwise dose increments. The cell viability and growth profiles of resistant sublines were examined. As the resistance indices increased...
Tailoring magnetic PLGA nanoparticles suitable for doxorubicin delivery
Tansik, Gulistan; YAKAR, ARZU; Gündüz, Ufuk (2013-12-07)
One of the main problems of current cancer chemotherapy is the lack of selectivity of anti-cancer drugs to tumor cells, which leads to systemic toxicity and adverse side effects. In order to overcome these limitations, researches on controlled drug delivery systems have gained much attention. Nanoscale-based drug delivery systems provide tumor targeting. Among many types of nanocarriers, superparamagnetic nanoparticles with their biocompatible polymer coatings can be targeted to an intented site by an exter...
Enantiomerically pure beta-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways
Chan, Mei-Ling; Yu, Chia-Chun; Hsu, Jui-Ling; Leu, Wohn-Jenn; Chan, She-Hung; Hsu, Lih-Ching; Liu, Shih-Ping; Ivantcova, Polina M.; Doğan, Özdemir; Braese, Stefan; KUDRYAVTSEV, Konstantin V; GUH, Jih Hwa (Impact Journals, LLC, 2017-11-14)
The use of peptides that target cancer cells and induce anticancer activities through various mechanisms is developing as a potential anticancer strategy. KUD983, an enantiomerically pure beta-dipeptide derivative, displays potent activity against hormone-refractory prostate cancer (HRPC) PC-3 and DU145 cells with submicromolar IC50. KUD983 induced G1 arrest of the cell cycle and subsequent apoptosis associated with down-regulation of several related proteins including cyclin D1, cyclin E and Cdk4, and the ...
Citation Formats
N. Tunçbağ and E. S. Ayar, “Leveraging the Molecular Signatures of Cancer for Dynamic Network Modeling,” Erdemli, Mersin, TÜRKİYE, 2022, p. 3067, Accessed: 00, 2023. [Online]. Available: https://hibit2022.ims.metu.edu.tr/.